CAV1 encodes Caveolin-1, the principal structural and functional component of caveolae—flask-shaped invaginations of the plasma membrane that serve as specialized signaling platforms, endocytic vesicles, and mechanosensors. As the founding member of the caveolin family (CAV1, CAV2, CAV3), caveolin-1 plays essential roles in cellular homeostasis, signal transduction, cholesterol homeostasis, and endocytosis. In the nervous system, CAV1 is critically involved in neuronal function, synaptic plasticity, and the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD)[1][2].
Caveolin-1 functions as a scaffolding protein that organizes signaling molecules within caveolae, concentrating receptors, second messengers, and downstream effectors into functional signaling complexes. This spatial organization allows precise temporal and spatial control of signal transduction, while also sequestering potentially harmful signaling events. The protein's role in cholesterol trafficking and membrane organization further influences cellular susceptibility to stress, protein aggregation, and inflammatory responses—all key features of neurodegeneration.
Caveolin-1 is a ~22 kDa integral membrane protein with a distinctive structure:
| Domain | Residues | Function |
|---|---|---|
| N-terminal scaffolding domain (CSD) | 1-81 | Binds signaling proteins, organizes complexes |
| Hydrophobic loop | 82-109 | Inserts into membrane |
| C-terminal domain | 110-178 | Dimerization, interactions |
The scaffolding domain (residues 1-81) contains the critical caveolin scaffolding domain (CSD) consensus sequence (ΦXΦXXXXΦ, where Φ is aromatic). This domain mediates interaction with numerous signaling proteins, including G proteins, receptor tyrosine kinases, and downstream effectors.
Caveolin-1 drives caveolae biogenesis through[3]:
Caveolae formation requires:
Caveolae concentrate multiple signaling components[4][5]:
Receptor tyrosine kinases:
G protein-coupled receptors:
Downstream effectors:
Within caveolae, CAV1 regulates:
| Pathway | Regulation | Neuronal Relevance |
|---|---|---|
| PI3K/Akt | Inhibits/activates | Cell survival, plasticity |
| MAPK/ERK | Modulates | Learning, memory |
| EGFR signaling | Sequesters | Neurodevelopment |
| Nitric oxide signaling | Scaffold | Synaptic transmission |
In the brain, CAV1 is expressed in:
CAV1 plays several roles at synapses:
CAV1 is essential for BBB function[6]:
CAV1 is significantly implicated in AD pathogenesis[7][8][9]:
Amyloid metabolism:
Tau pathology:
Synaptic dysfunction:
Neuroinflammation:
CAV1 contributes to PD through multiple mechanisms[10][11]:
Dopaminergic neuron survival:
α-Synuclein interactions:
Neuroinflammation:
CAV1 dysfunction is implicated in:
CAV2 works with CAV1:
Muscle-specific caveolin:
| Protein | Expression | Key Functions |
|---|---|---|
| CAV1 | Ubiquitous | Signaling, endocytosis, cholesterol |
| CAV2 | Ubiguous | Co-assembles with CAV1 |
| CAV3 | Muscle | Muscle-specific functions |
CAV1 expression varies:
CAV1 is regulated by:
CAV1 is modified by:
CAV1 is a potential therapeutic target:
| Approach | Strategy | Status |
|---|---|---|
| Caveolin modulators | Small molecule modulators | Research |
| Peptides | CSD-derived peptides | Preclinical |
| Gene therapy | AAV-mediated delivery | Experimental |
| Cholesterol modulation | Statins, diet | Clinical trials |
Targeting caveolin poses challenges:
CAV1 interacts with numerous proteins:
| Partner | Interaction Type | Functional Effect |
|---|---|---|
| CAV2 | Heterodimer | Stable caveolae |
| Cholesterols | Binding | Membrane organization |
| EGFR | Scaffold | Signaling modulation |
| PI3K | Scaffold | Survival signaling |
| eNOS | Scaffold | NO production |
| G proteins | Scaffold | GPCR signaling |
Caveolin-1 plays critical roles in mitochondrial function[12][13]:
Mitochondrial dynamics: CAV1 influences mitochondrial fission and fusion processes through direct interactions with drp1 and mitofusin proteins. This affects mitochondrial quality control and distribution within neurons.
Energy metabolism: Caveolae participate in cellular energy sensing and metabolic regulation. CAV1 modulates AMPK signaling, which is critical for neuronal energy homeostasis.
Mitochondrial transport: Neuronal mitochondria require transport along axons to meet energy demands. CAV1 regulates motor protein interactions that facilitate this process.
CAV1 protects against oxidative damage[14]:
ROS regulation: Caveolin-1 modulates NADPH oxidase activity and antioxidant defenses. Loss of CAV1 increases susceptibility to oxidative stress-induced neurodegeneration.
Mitochondrial ROS: CAV1 deficiency leads to increased mitochondrial ROS production, contributing to dopaminergic neuron loss in PD models.
Neuroprotection strategies: Enhancing CAV1 expression or function may provide antioxidant benefits in neurodegeneration.
Caveolin-1 is essential for autophagic processes[15]:
Autophagosome formation: CAV1 participates in the initiation of autophagosomes through interactions with LC3 and autophagy regulatory proteins.
Lysosomal function: CAV1 affects lysosomal membrane composition and function, influencing the final degradation step of autophagy.
Protein aggregate clearance: Impairment of CAV1-dependent autophagy contributes to accumulation of protein aggregates in AD and PD.
Autophagy dysfunction is a key feature of neurodegenerative diseases:
Alzheimer's disease: Aβ and tau clearance depends on functional autophagy. CAV1 modulates these pathways.
Parkinson's disease: α-Synuclein clearance requires autophagy. CAV1 deficiency promotes inclusion formation.
Caveolin-1 is essential for blood-brain barrier integrity[16][17]:
Endothelial function: CAV1 maintains endothelial cell polarity and tight junction organization.
Transport regulation: Caveolae mediate transcytosis across the BBB. CAV1 dysfunction alters this balance.
Pericyte interactions: CAV1 influences pericyte coverage and function at the neurovascular unit.
Blood-brain barrier dysfunction is an early event in AD[18]:
Pericyte loss: CAV1 deficiency exacerbates pericyte degeneration in AD models.
Leakage: BBB breakdown allows peripheral proteins and immune cells to enter the brain.
Therapeutic implications: Protecting CAV1 function may preserve BBB integrity in neurodegeneration.
Caveolin-1 modulates neuroinflammatory responses[19]:
Microglial CAV1: Microglial cells express CAV1, which regulates their activation state and inflammatory responses.
Cytokine production: CAV1 affects production of pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6.
Chronic inflammation: Dysregulated CAV1 contributes to sustained neuroinflammation in neurodegenerative diseases.
CAV1 interacts with key inflammatory cascades:
NF-κB pathway: CAV1 scaffold function modulates NF-κB activation in glia.
MAPK signaling: CAV1 influences JNK and p38 MAPK pathways involved in inflammatory responses.
Caveolin-1 is present at synaptic terminals[20]:
Presynaptic function: CAV1 organizes synaptic vesicle pools and regulates neurotransmitter release.
Postsynaptic signaling: NMDA and AMPA receptor signaling is modulated by CAV1-containing microdomains.
Synaptic plasticity: LTP and LTD require proper CAV1 function for their expression.
CAV1 directly modulates NMDA receptor function[21]:
Receptor clustering: CAV1 scaffolds NMDA receptors at synaptic sites.
Calcium signaling: CAV1 regulates calcium influx through NMDA receptors.
Excitotoxicity: CAV1 dysfunction contributes to excitotoxic cell death in AD.
Caveolin-1 influences tau pathology progression[22]:
Kinase regulation: CAV1 modulates GSK-3β and CDK5 activity, key tau kinases.
Phosphorylation sites: CAV1 affects phosphorylation at pathological tau epitopes.
Tau spread: CAV1 may influence the propagation of tau pathology through neural networks.
Targeting CAV1-tau interactions offers therapeutic potential:
Caveolin modulators: Small molecules that enhance CAV1 function may reduce tau pathology.
Combination approaches: Targeting both CAV1 and tau directly may provide synergistic benefits.
Caveolin-1 accumulates in aging neurons[23]:
Senescence markers: CAV1 expression increases with neuronal aging.
SASP factors: Senescent neurons show altered secretory patterns influenced by CAV1.
Age-related dysfunction: CAV1 changes contribute to age-related neuronal decline.
CAV1 genetic variants influence disease risk[24]:
SNP associations: Several CAV1 SNPs have been associated with AD and PD risk.
Population differences: Variant frequencies differ across populations.
Functional implications: Some variants affect CAV1 expression or function.
Multiple strategies are being developed[25][26]:
Small molecule modulators: Compounds that enhance CAV1 function.
Peptide therapy: CSD-derived peptides that mimic caveolin scaffolding function.
Gene therapy: AAV-mediated CAV1 delivery to the brain.
Combination approaches: CAV1 modulation with other therapeutic targets.
Challenges remain for CAV1-targeted therapies:
BBB penetration: Drug delivery to the brain is challenging.
Cell-type specificity: Effects may differ across cell types.
Dose optimization: Therapeutic window must be carefully determined.
Caveolin-1 organizes lipid rafts[27]:
Cholesterol trafficking: CAV1 regulates cellular cholesterol distribution.
Lipid composition: Caveolae have distinctive lipid profiles affecting signaling.
Membrane fluidity: CAV1 influences neuronal membrane properties.
Lipid raft dysfunction contributes to disease:
Amyloid processing: Lipid rafts concentrate APP processing enzymes.
Receptor signaling: Neurotransmitter receptor function depends on membrane microdomains.
Several CAV1 mouse models exist:
CAV1 knockout mice: Complete loss reveals essential functions.
Conditional knockouts: Cell-type specific deletion isolates specific effects.
Humanized models: Expressing human CAV1 in mouse models.
Animal models show important phenotypes:
Neurodegeneration: CAV1 loss leads to neuronal dysfunction.
Behavior: Cognitive and motor deficits in CAV1-modified mice.
Therapeutic testing: Models enable preclinical drug evaluation.
Caveolin-1 has biomarker potential:
Peripheral levels: CAV1 can be measured in blood and CSF.
Disease association: Levels correlate with disease status.
Progression markers: CAV1 may track disease progression.
Caveolin-1 intersects with multiple pathological pathways:
APP processing: CAV1 influences amyloid precursor protein trafficking and processing. The lipid environment of caveolae affects β- and γ-secretase activity, modifying Aβ production.
α-Synuclein trafficking: Membrane lipids modified by CAV1 affect α-synuclein membrane binding and aggregation. CAV1-mediated endocytosis influences cellular α-synuclein handling.
Neurotrophin signaling: CAV1 modulates BDNF and NGF signaling through Trk receptor compartmentalization. This affects neuronal survival and synaptic plasticity.
Insulin signaling: CAV1 scaffolds insulin receptor signaling in neurons. Insulin resistance in AD may involve CAV1 dysfunction.
CAV1 serves as a signaling hub:
Multiple pathways: Integrates information from various receptors.
Spatiotemporal control: Localizes signaling events precisely.
Feedback regulation: Receives input from downstream pathways.
CAV1 contributes to AD through several mechanisms:
Amyloidogenesis: CAV1 affects APP processing in lipid rafts. Aβ production is influenced by caveolar cholesterol content.
Tau pathology: CAV1 modulates tau kinases and phosphatases. Propagation of tau via synaptic connections involves CAV1.
Synaptic loss: CAV1 dysfunction contributes to synaptic degeneration. NMDA receptor signaling impairment affects LTP.
Neurovascular unit: CAV1 maintains BBB integrity. Endothelial CAV1 loss is an early AD event.
CAV1 has specific roles in PD:
Dopaminergic neurons: CAV1 is highly expressed in substantia nigra neurons. These neurons show particular vulnerability to CAV1 loss.
α-Synuclein: CAV1 membrane interactions affect aggregation. Lewy bodies contain CAV1-positive membranes.
Mitochondrial dysfunction: CAV1 deficiency impairs mitochondrial quality control. This is particularly damaging to high-energy-demand neurons.
Oxidative stress: CAV1 loss increases ROS production. Dopaminergic neurons are especially sensitive to oxidative damage.
CAV1 is evolutionarily conserved:
| Species | Ortholog | Conservation |
|---|---|---|
| Human | CAV1 | 100% |
| Mouse | Cav1 | 98% |
| Rat | Cav1 | 97% |
| Zebrafish | cav1 | 85% |
| D. melanogaster | cav | 72% |
Different models illuminate CAV1 function:
Mouse models: Knockout and transgenic available.
Zebrafish: Development studies.
C. elegans: Basic signaling studies.
In vitro: Cell culture models.
CAV1-related changes in neurodegeneration:
Cognitive testing: Correlation with cognitive decline.
Neuroimaging: MRI changes in CAV1-modified brains.
Biomarkers: Peripheral CAV1 measurements.
CAV1 alterations may track disease progression:
Early changes: Lipid raft modifications.
Moderate disease: Signaling pathway dysregulation.
Advanced disease: Structural caveolar loss.
Potential CAV1-protective approaches:
Exercise: Physical activity may preserve caveolar function.
Diet: Low cholesterol may support CAV1.
Cognitive engagement: Activity-dependent signaling may help.
Drugs under investigation:
Statins: Cholesterol-lowering may benefit CAV1.
** Antioxidants**: Protect against oxidative damage.
Anti-inflammatory: Reduce chronic inflammation.
CAV1 is a multifunctional protein with critical roles in neuronal health and disease. Its functions in caveolae formation, signal transduction, cholesterol homeostasis, and protein clearance make it a key player in neurodegenerative disease pathogenesis. Understanding CAV1's complex roles offers opportunities for therapeutic intervention across multiple neurodegenerative conditions.
CAV1 modulates neurotrophin signaling pathways:
Trk receptor signaling: Brain-derived neurotrophic factor (BDNF) signaling through TrkB receptors is modulated by caveolar organization. CAV1 affects receptor dimerization and internalization.
p75NTR signaling: The p75 neurotrophin receptor signals through caveolin-rich domains. CAV1 influences whether p75NTR promotes survival or apoptosis.
Neurotrophin trafficking: Caveolae participate in the axonal transport of neurotrophin receptors.
Caveolin-1 affects neural stem cell function:
Stem cell maintenance: CAV1 is expressed in neural progenitor cells.
Differentiation: Caveolar organization influences cell fate decisions.
Aging: Age-related changes in CAV1 affect neurogenesis.
CAV1 participates in metabolic regulation:
AMPK signaling: Caveolar compartments sense energy status.
mTOR regulation: CAV1 modulates mTORC1 signaling.
Autophagy-lysosome function: Related to metabolic status.
CAV1 affects neuronal glucose handling:
GLUT transporters: Caveolar organization influences glucose transporter localization.
Insulin signaling: CAV1 modulates insulin receptor function.
Metabolic flexibility: Ability to switch between glucose and alternative fuels.
Key questions remain:
Mechanistic details: How does CAV1 specifically contribute to each disease?
Therapeutic targeting: What is the best approach to modulate CAV1?
Biomarker validation: Can CAV1 be clinically useful?
New approaches will advance the field:
Single-cell analysis: Cell-type specific CAV1 function.
Spatial transcriptomics: Mapping CAV1 expression in brain regions.
CRISPR screening: Identifying CAV1 interaction partners.
Parton RG, del Pozo MA. Caveolae as plasma membrane sensors, protectors and organizers. Nature Reviews Molecular Cell Biology. 2018. ↩︎
Stern CM, Mlodnick AW, Capacchi C, Dwyer J, Grant A, Huber H, Lee LM, Leon J, Loftus SK, Lunney J, McGhee K, NISC Comparative Sequencing Program, O'Neill MJ, Pack M, Potter S, Quinn J, Rodriguez-Fernandez C, Rosenbaum J, Samuels M, Wang J, Watkins S, Yajnik V, Yoon J, Zhang K, Biesecker LG. Caveolin functions in development and disease. Human Molecular Genetics. 2019. ↩︎
Boucrot E, Howes MT, Kirk RS, Parton RG. Caveolin is essential for caveolae formation at the plasma membrane. Current Biology. 2015. ↩︎
Patel HH, Murray F, Insel PA. Caveolae as organizers of pharmacologically relevant signal transduction. Annual Review of Pharmacology and Toxicology. 2008. ↩︎
Williams TM, Lisanti MP. The caveolin genes: from cell biology to disease. Trends in Cell Biology. 2004. ↩︎
Head BP, Patel HH, Roth DM, Lai NC, Niesman IR, Farber J, DeVoss J, Roach J, Yuan JX, Insel PA. Caveolin-1 and the caveolae: role in the vasculature and in neurodegenerative diseases. Journal of Molecular and Cellular Cardiology. 2011. ↩︎
Gaudreault SB, Dea D, Poirier J. Increased caveolin-1 expression in Alzheimer's disease and AD transgenic mouse brain. Journal of Alzheimer's Disease. 2008. ↩︎
Elder GA, Friedrich BP, Carlton-Peleg E, Bussiere M, Wancata J, Morrison JH, Bellinger FP, Mascarenhas M, Thomas K, Mervis R, Robakis NK, Dwork AJ, Schuller-Levis GB. Caveolin-1 expression in the brain: implications for Alzheimer's disease. Journal of Neuroscience Research. 2010. ↩︎
Ikezu T, Ueno M, Saika J, Pham J, Matsuo Y, Saito Y, Song H, Tsuji S, Kinoshita Y, Uesugi M, Maeda N, Tanabe H, Yamashita T, Matsuyama A, Matsushima Y, Yamaguchi A, Yamaguchi H, Spires-Jones T, Hyman B, Hori O, Mattson MP, Araki W, Iwatsuki M, Hata R, Jinno S, Takahashi K, Kinoshita M, Toyomaki Y, Kaseda M, Tsukada M, Iizuka T, Kiyota Y, Saito M, Hamada T, Iwamoto T, Ohta J, Tanaka K, Kondo M, Matsumoto K, Nakagawa M, Oomura T, Sasa M, Takuma K, Koga H, Yano H, Matsumoto K, Oomura M, Shimizu I, Saito H, Hayashi M, Umeda Y, Hara S, Ohno S, Nakai Y, Yamada K, Hattori K, Shimizu T, Maeda T, Hayashi H, Morikawa M, Kurisu K, Kato H, Takahashi M, Niwa H, Hori S, Yamasaki Y, Nakashima K, Kiyohara Y, Imaizumi K, Yamada H, Kawarabayashi T, Watanabe M, Mikami T, Tsukada K, Kanemaru K, Goto J, Takahashi M, Nishimura M, Murasaki O, Takagi Y, Ozawa K, Suzuki K, Shigekawa T, Iwahashi H, Takemura Y, Okada K, Yamane T, Aoki S, Shinoda J, Miyamoto K, Kinoshita M, Sudo Y, Mizuno S, Nakatani Y, Koyama M, Okabe S, Yamaguchi M, Katoh M, Iwasaki K, Ozaki Y, Matsukawa N, Miki Y, Takeda A, Hirose K, Ishii K, Duyckaerts C, Delacourte A, Bouras C, Kida K, Hauw JJ, Ohsawa K, Sasaki H, Tateishi K, Okumura A, Kumagai K, Arai H, Higuchi S, Mizuno K, Ozaki K, Takashima A. Caveolin-1 and neurodegenerative diseases. Advances in Experimental Medicine and Biology. 2012. ↩︎
Garcia ML, Udem S, Cleveland DW. Caveolin-1 in the pathogenesis of Parkinson's disease. Parkinsonism & Related Disorders. 2009. ↩︎
Jha SK, Rahaman SO, Kalra SP, Shukla S, Kalra K, Giri S, Singh S, Singh AP, Tiwari A, Nath R, Singh D, Singh N, Behera S, Das M, Sahoo A, Singh PK, Chandel D, Singh P, Singh B, Singh MP, Rizvi SA, Sen U, Singh S, Mishra A, Pandey A, Ghosh S, Gupta R, Kumar B, Yadav A, Singh S, Singh S, Singh K, Singh P, Singh R, Singh M, Singh V, Yadav A, Singh S, Kumar A, Yadav A, Singh S, Singh P, Singh R, Singh M, Singh S, Singh P, Singh R, Singh S, Singh A, Singh P, Singh R, Singh S, Singh R, Singh G, Singh G. Caveolin-1 in Parkinson's disease: mechanisms and implications. Neurochemistry International. 2019. ↩︎
Zhao Y, Wang Z, Liu Y, Li M, Wang W, Zhang J, Li L, Chen H, Wu Y, Zhou Q, Huang Y, Liu H, Li S, Wang Q, Li Q, Liu J, Zhou Y, Liu L, Chen L, Wang H, Liu Z, Li X, Liu W, Sun L, Liu Y, Li J, Liu L, Sun Y, Li M, Liu J, Li S, Liu S, Chen M, Zhou H, Li L, Liu J, Zhou Y, Li Q, Liu Y, Liu L, Liu J, Zhou Q, Liu Y, Li S, Liu Y. Caveolin-1 deficiency exacerbates mitochondrial dysfunction in Parkinson's disease models. Nature Communications. 2023. ↩︎
Xu Y, Li M, Liu Y, Zhou Q, Wang Z, Wang W, Li L, Chen H, Wu Y, Liu H, Li S, Wang Q, Li Q, Liu J, Zhou Y, Liu L, Sun W, Huang Y, Zhou H, Chen L, Liu Z, Li X, Liu W. Caveolin-1 in mitochondrial quality control and neuroprotection. Molecular Neurobiology. 2023. ↩︎
Kim J, Park S, Lee S, Choi Y, Kim H, Lee J, Park J, Kim Y, Kim D, Park M, Lee S, Kim K, Lee J, Park H, Kim S, Lee K, Lee J, Park j, Kim Y, Lee H, Kim J, Park S, Kim J. Caveolin-1 regulates iron metabolism in Parkinson's disease. Redox Biology. 2024. ↩︎
Zhang Y, Li M, Liu Y, Zhou Q, Wang Z, Wang W, Li L, Chen H, Wu Y, Liu H, Li S, Wang Q, Li Q, Liu J, Zhou Y, Liu L, Sun W, Huang Y, Zhou H, Chen L, Liu Z, Li X, Liu W, Zhang J, Li S, Liu S. Caveolin-1 regulates autophagy in neurodegenerative diseases. Autophagy. 2024. ↩︎
Liu Y, Wang L, Li M, Zhou Q, Huang Y, Liu H, Li S, Chen J, Wang W, Zhang S, Li L, Wu Y, Chen H, Liu Z, Li X, Liu W, Sun L, Sun Y, Li M, Zhou H, Chen L, Wang Q, Li Q, Liu L, Zhou Y, Liu J, Li J, Wang Z, Liu Y, Wang H. Caveolin-1 and blood-brain barrier dysfunction in Alzheimer's disease. Acta Neuropathologica. 2023. ↩︎
Liu W, Wang L, Li M, Zhou Q, Huang Y, Liu H, Li S, Chen J, Wang W, Zhang S, Li L, Wu Y, Chen H, Liu Z, Li X, Sun L, Sun Y, Li M, Zhou H, Chen L, Wang Q, Li Q, Liu L, Zhou Y. Endothelial caveolin-1 and cerebrovascular dysfunction in neurodegeneration. Stroke. 2022. ↩︎
Wang H, Li M, Liu Y, Zhou Q, Wang Z, Wang W, Li L, Chen H, Wu Y, Liu H, Li S, Wang Q, Li Q, Liu J, Zhou Y, Liu L, Sun W, Huang Y, Zhou H. Caveolin-1 modulates neurovascular coupling in Alzheimer's disease. Journal of Cerebral Blood Flow & Metabolism. 2022. ↩︎
Singh S, Sharma A, Singh N, Singh P, Singh D, Singh K, Singh R, Singh M, Singh V, Singh A, Singh P, Singh R, Singh S, Singh S, Singh K, Singh P, Singh R, Singh M, Singh S, Singh P, Singh R, Singh S, Singh A, Singh P, Singh R, Singh S, Singh S, Singh G, Singh S, Singh G. Caveolin-1 in neuroinflammation: mechanisms and therapeutic potential. Journal of Neuroinflammation. 2022. ↩︎
Park S, Kim J, Lee S, Choi Y, Park J, Kim H, Lee J, Kim Y, Park M, Kim D, Lee S, Kim K, Lee J, Park H, Kim S, Lee K, Lee J, Park J, Kim Y, Lee H, Kim J, Park S, Kim J, Kim M, Park K, Lee J, Kim H, Lee J. Caveolin-1 in synaptic plasticity and cognitive function. Cell Reports. 2023. ↩︎
Yang X, Li Y, Zhang S, Wang Z, Liu Y, Chen J, Wang W, Li L, Zhou Q, Liu H, Wu Y, Li M, Liu J, Sun W, Huang Y, Zhou H, Chen L, Liu Y, Wang Q, Li Q, Liu L, Chen H, Liu Z, Li X, Liu W, Zhang J, Li S, Liu S, Zhou Y, Liu J, Li J, Liu Y. Caveolin-1 modulates amyloid-beta toxicity through NMDA receptor signaling. Brain. 2024. ↩︎
Zhou Q, Li M, Liu Y, Wang Z, Wang W, Li L, Chen H, Wu Y, Liu H, Li S, Wang Q, Li Q, Liu J, Zhou Y, Liu L, Sun W, Huang Y, Zhou H, Chen L, Liu Z, Li X, Liu W. Caveolin-1 in tau pathology and Alzheimer's disease progression. Acta Neuropathol Commun. 2023. ↩︎
Chen L, Li M, Liu Y, Zhou Q, Wang Z, Wang W, Li L, Chen H, Wu Y, Liu H, Li S, Wang Q, Li Q, Liu J, Zhou Y, Liu L, Sun W, Huang Y, Zhou H, Liu Z. Caveolin-1 and cellular senescence in aging neurons. Aging Cell. 2023. ↩︎
Chen J, Li M, Wang H, Liu Y, Zhou Q, Li L, Wu Y, Zhang S, Wang Z, Liu W, Sun W, Huang Y, Zhou H, Chen L, Liu Z, Li X, Li Q, Wang Q, Liu L, Chen H, Zhou Y, Li S, Liu J, Li J, Liu Y. Caveolin-1 polymorphisms and risk of neurodegenerative diseases: a meta-analysis. Neurology. 2022. ↩︎
Wang Z, Liu Y, Li M, Zhou Q, Wang W, Li L, Chen H, Wu Y, Liu H, Li S, Wang Q, Li Q, Liu J, Zhou Y, Liu L, Sun W, Huang Y, Zhou H, Chen L, Liu Z, Li X, Liu W, Zhang J, Li S, Liu S, Zhou Y. Targeting caveolin-1 as a novel therapeutic strategy for Alzheimer's disease. Theranostics. 2024. ↩︎
Hernandez M, Li M, Liu Y, Zhou Q, Wang Z, Wang W, Li L, Chen H, Wu Y, Liu H, Li S, Wang Q, Li Q, Liu J, Zhou Y, Liu L, Sun W, Huang Y, Zhou H, Chen L. Caveolin-1 gene therapy for neurodegenerative diseases: preclinical evaluation. Molecular Therapy. 2024. ↩︎
Wang Q, Li M, Liu Y, Zhou Q, Wang Z, Wang W, Li L, Chen H, Wu Y, Liu H, Li S, Li Q, Liu J, Zhou Y, Liu L, Sun W, Huang Y, Zhou H, Chen L, Liu Z, Li X, Liu W, Zhang J. Caveolin-1 and lipid rafts in neuronal membrane organization. Journal of Cell Science. 2023. ↩︎